|
1
|
Kennedy DA, Woodland C and Koren G: Lead
exposure, gestational hypertension and pre-eclampsia: A systematic
review of cause and effect. J Obstet Gynaecol. 32:512–517. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Huang YH, Chen YP, Liang CC, Chang YL and
Hsieh CC: Impetigo herpetiformis with gestational hypertension: A
case report and literature review. Dermatology. 222:221–224. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhu YC, Sun Y and Yang HX: Chronic
hypertension superimposed on preeclampsia at 13 gestational weeks:
A case report with review. Chin Med J (Engl). 125:2067–2069.
2012.PubMed/NCBI
|
|
4
|
Schoenaker DA, Soedamah-Muthu SS and
Mishra GD: The association between dietary factors and gestational
hypertension and pre-eclampsia: A systematic review and
meta-analysis of observational studies. BMC Med. 12:1572014.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pengo MF, Rossi GP and Steier J:
Obstructive sleep apnea, gestational hypertension and preeclampsia:
A review of the literature. Curr Opin Pulm Med. 20:588–594. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zainul Rashid MR, Lim JF, Nawawi NH,
Luqman M, Zolkeplai MF, Rangkuty HS, Mohamad Nor NA, Tamil A, Shah
SA, Tham SW and Schindler AE: A pilot study to determine whether
progestogen supplementation using dydrogesterone during the first
trimester will reduce the incidence of gestational hypertension in
primigravidae. Gynecol Endocrinol. 30:217–220. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang YA, Chughtai AA, Farquhar CM, Pollock
W, Lui K and Sullivan EA: Increased incidence of gestational
hypertension and preeclampsia after assisted reproductive
technology treatment. Fertil Steril. 105:920–926.e922. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hua X, Zhang J, Guo Y, Shen M, Gaudet L,
Janoudi G, Walker M and Wen SW: Effect of folic acid
supplementation during pregnancy on gestational
hypertension/preeclampsia: A systematic review and meta-analysis.
Hypertens pregnancy. 35:447–460. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Basaran A, Basaran M, Topatan B and Martin
JN Jr: Effect of chorionic villus sampling on the occurrence of
preeclampsia and gestational hypertension: An updated systematic
review and meta-analysis. J Turk Ger Gynecol Assoc. 17:65–72. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang C, Li J and Wang K: Clinical
analysis of the therapeutic effect of patients with gestational
hypertension combined with obstructive sleep apnea hypopnea
syndrom. Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi.
28:1521–1522. 2014.(In Chinese). PubMed/NCBI
|
|
11
|
Sakar MN, Atay AE, Demir S, Bakir VL,
Demir B, Balsak D, Akay E, Ulusoy AI and Verit FF: Association of
endothelial nitric oxide synthase gene G894T polymorphism and serum
nitric oxide levels in patients with preeclampsia and gestational
hypertension. J Mater Fetal Neonatal Med. 28:1907–1911. 2015.
View Article : Google Scholar
|
|
12
|
Tovar-Rodriguez JM, Medel-Lagunes Idel C,
Acosta-Altamirano G and Vargas-Hernandez VM: Clinic characteristics
of patients with trophoblastic gestational disease complicate with
hypertension. Ginecol Obstet Mex. 81:578–586. 2013.(In Spanish).
PubMed/NCBI
|
|
13
|
Vasapollo B, Novelli GP, Gagliardi G,
Tiralongo GM, Pisani I, Manfellotto D, Giannini L and Valensise H:
Medical treatment of early-onset mild gestational hypertension
reduces total peripheral vascular resistance and influences
maternal and fetal complications. Ultrasound Obstet Gynecol.
40:325–331. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Davidovich IM, Bloshchinskaia IA and
Petrichko TA: Gestational arterial hypertension. Mechanisms of
formation. Treatment with normodipin. Ter Arkh. 75:50–54. 2003.(In
Russian).
|
|
15
|
Munakata M, Aihara A, Nunokawa T, Ito N,
Imai Y, Ito S and Yoshinaga K: The influence of one-year treatment
by angiotensin converting enzyme inhibitor on baroreflex
sensitivity and flow-mediated vasodilation of the brachial artery
in essential hypertension-comparison with calcium channel blockers.
Clin Exp Hypertens. 25:169–181. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hu Y and Zhu J: Quality of life of
patients with mild hypertension treated with captopril: A
randomized double-blind placebo-controlled clinical trial. Chin Med
J (Engl). 112:302–307. 1999.PubMed/NCBI
|
|
17
|
Rudner S and Browne P: Case report:
Management of secondary hypertension in a feline with the use of
transdermal prazosin. Int J Pharm Compd. 14:488–491.
2010.PubMed/NCBI
|
|
18
|
Iwatsubo K and Umemura S: Alpha adrenergic
receptor blockers for patients with hypertension. Nihon Rinsho.
6:294–299. 2006.(In Japanese).
|
|
19
|
Zhao LS and Xu CY: Effect of prazosin on
diabetic nephropathy patients with positive α1-adrenergic receptor
autoantibodies and refractory hypertension. Exp Ther Med.
9:177–182. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Raeissadat SA, Rayegani SM, Hassanabadi H,
Fathi M, Ghorbani E, Babaee M and Azma K: Knee osteoarthritis
injection choices: Platelet-rich plasma (PRP) versus hyaluronic
acid (A one-year randomized clinical trial). Clin Med Insights
Arthritis Musculoskelet Disord. 8:1–8. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Rodriguez-Merchan EC: Intraarticular
injections of platelet-rich plasma (PRP) in the management of knee
osteoarthritis. Arch Bone Jt Surg. 1:5–8. 2013.PubMed/NCBI
|
|
22
|
Goetz RM and Holtz J: Enhanced
angiotensin-converting enzyme activity and impaired
endothelium-dependent vasodilation in aortae from hypertensive
rats: Evidence for a causal link. Clin Sci (Lond). 97:165–174.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Paiva L, Lima E, Neto AI and Baptista J:
Angiotensin I-converting enzyme (ACE) inhibitory activity of fucus
spiralis macroalgae and influence of the extracts storage
temperature-A short report. J Pharm Biomed Anal. 131:503–507. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mattar MM, Morad MA, El Husseiny NM, Ali
NH and El Demerdash DM: Correlation between JAK2 allele burden and
pulmonary arterial hypertension and hematological parameters in
philadelphia negative JAK2 positive myeloproliferative neoplasms.
An egyptian experience. Ann Hematol. 95:1611–1616. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gobbi A, Lad D and Karnatzikos G: The
effects of repeated intra-articular PRP injections on clinical
outcomes of early osteoarthritis of the knee. Knee Surg Sports
Traumatol Arthrosc. 23:2170–2177. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Filardo G, Kon E, DI Matteo B, DI Marino
A, Sessa A, Merli ML and Marcacci M: Leukocyte-poor PRP application
for the treatment of knee osteoarthritis. Joints. 1:112–120.
2013.PubMed/NCBI
|
|
27
|
Franklin HR, Simonetti GP, Dubbelman AC,
ten Bokkel Huinink WW, Taal BG, Wigbout G, Mandjes IA, Dalesio OB
and Aaronson NK: Toxicity grading systems. A comparison between the
WHO scoring system and the common toxicity criteria when used for
nausea and vomiting. Ann Oncol. 5:113–117. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Boss DS, Glen H, Beijnen JH, Keesen M,
Morrison R, Tait B, Copalu W, Mazur A, Wanders J, O'Brien JP, et
al: A phase I study of E7080, a multitargeted tyrosine kinase
inhibitor, in patients with advanced solid tumours. Br J Cancer.
106:1598–1604. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Woodworth T, Furst DE, Alten R, Bingham CO
III, Yocum D, Sloan V, Tsuji W, Stevens R, Fries J, Witter J, et
al: Standardizing assessment and reporting of adverse effects in
rheumatology clinical trials II: The rheumatology common toxicity
criteria v.2.0. J Rheumatol. 34:1401–1414. 2007.PubMed/NCBI
|
|
30
|
Van Guilder GP, Pretorius M, Luther JM,
Byrd JB, Hill K, Gainer JV and Brown NJ: Bradykinin type 2 receptor
BE1 genotype influences bradykinin-dependent vasodilation during
angiotensin-converting enzyme inhibition. Hypertension. 51:454–459.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Reusz GS and Kis E, Cseprekál O, Szabó AJ
and Kis E: Captopril-enhanced renal scintigraphy in the diagnosis
of pediatric hypertension. Pediatr Nephrol. 25:185–189. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hanon O, Giacomino A, Troy S, Bernaud C,
Girerd X and Weber S: Efficacy of and tolerance to prolonged
release prazosin in patients with hypertension and non-insulin
dependent diabetes. Ann Cardiol Angeiol (Paris). 49:390–396.
2000.(In French). PubMed/NCBI
|
|
33
|
Hall DR, Odendaal HJ, Steyn DW and Smith
M: Nifedipine or prazosin as a second agent to control early severe
hypertension in pregnancy: A randomised controlled trial. BJOG.
107:759–765. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Joglekar SJ and Nanivadekar AS: A
randomized, controlled, multicenter study to compare prazosin GITS
with enalapril in hypertensive patients with diabetes mellitus.
Bombay Hypertension Study Group. J Assoc Physicians India. 1:52–62.
1998.PubMed/NCBI
|
|
35
|
Joglekar SJ, Jaguste V and Nanivadekar AS:
Prazosin GITS vs atenolol in patients with hypertension and normal
lipid profile: A randomized, controlled multicenter study.
Hyderabad Hypertension Study Group. J Assoc Physicians India.
1:41–51. 1998.PubMed/NCBI
|
|
36
|
Morishita S, Hagihara M, Itabashi M, Ishii
Y, Yamamoto W, Numata A, Motohashi K, Matsumoto K, Fujisawa S and
Nakajima H: Development of pulmonary arterial hypertension during
oral dasatinib therapy for chronic myelogenous leukemia. Rinsho
Ketsueki. 57:999–1003. 2016.PubMed/NCBI
|
|
37
|
Galappatthy P, Waniganayake YC, Sabeer MI,
Wijethunga TJ, Galappatthy GK and Ekanayaka RA: Leg edema with
(S)-amlodipine vs conventional amlodipine given in triple therapy
for hypertension: A randomized double blind controlled clinical
trial. BMC Cardiovasc Disord. 16:1682016. View Article : Google Scholar : PubMed/NCBI
|
